Corcept Therapeutics Q1 2025: Unpacking Key Contradictions on Korlym Demand, Relacorilant NDA, and Clinical Strategies
Generated by AI AgentAinvest Earnings Call Digest
Tuesday, May 6, 2025 7:34 pm ET1min read
CORT--
Pharmacy operations and Korlym demand, Relacorilant NDA acceptance and AdCom expectations, ROSELLA study endpoints and strategy, Relacorilant's pivotal study and approval pathPATH--, and impact of CATALYST results on Korlym's performance, are the key contradictions discussed in Corcept Therapeutics' latest 2025Q1 earnings call.
Revenue and Financial Performance:
- Corcept TherapeuticsCORT-- reported revenue of $157.2 million for Q1 2025, compared to $146.8 million in Q1 2024, with a reiterated 2025 revenue guidance of $900 million to $950 million.
- The increase in revenue was driven by increased patient growth and screening for hypercortisolism.
Patent Litigation and Legal Status:
- Corcept is appealing a decision against its lawsuit to block Teva's generic version of Korlym, with the Federal Circuit Court of Appeals yet to schedule oral arguments.
- If Corcept prevails, Teva would lose FDA approval for its product until 2037.
Oncology Program and Clinical Results:
- The ROSELLA trial in platinum-resistant ovarian cancer met primary endpoints, showing a 30% reduction in disease progression risk with relacorilant, with an expected NDA submission in Q4 2025.
- The positive results support cortisol modulation's role in cancer treatment and expand Corcept's oncology portfolio.
Endocrinology Business and Market Growth:
- The number of Korlym prescriptions in Q1 2025 was nearly double compared to the same period in 2024, driven by increased screening and treatment of hypercortisolism.
- Growth is expected to continue, driven by the CATALYST study's results and the expansion of the sales force.
Pharmacy Operations and Business Impact:
- The first quarter results were affected by insufficient capacity at the pharmacy vendor, leading to delayed drug shipments to patients.
- The issue has been resolved, with March and April seeing record tablet dispenses, and Corcept is exploring a broader distribution network for relacorilant.
Revenue and Financial Performance:
- Corcept TherapeuticsCORT-- reported revenue of $157.2 million for Q1 2025, compared to $146.8 million in Q1 2024, with a reiterated 2025 revenue guidance of $900 million to $950 million.
- The increase in revenue was driven by increased patient growth and screening for hypercortisolism.
Patent Litigation and Legal Status:
- Corcept is appealing a decision against its lawsuit to block Teva's generic version of Korlym, with the Federal Circuit Court of Appeals yet to schedule oral arguments.
- If Corcept prevails, Teva would lose FDA approval for its product until 2037.
Oncology Program and Clinical Results:
- The ROSELLA trial in platinum-resistant ovarian cancer met primary endpoints, showing a 30% reduction in disease progression risk with relacorilant, with an expected NDA submission in Q4 2025.
- The positive results support cortisol modulation's role in cancer treatment and expand Corcept's oncology portfolio.
Endocrinology Business and Market Growth:
- The number of Korlym prescriptions in Q1 2025 was nearly double compared to the same period in 2024, driven by increased screening and treatment of hypercortisolism.
- Growth is expected to continue, driven by the CATALYST study's results and the expansion of the sales force.
Pharmacy Operations and Business Impact:
- The first quarter results were affected by insufficient capacity at the pharmacy vendor, leading to delayed drug shipments to patients.
- The issue has been resolved, with March and April seeing record tablet dispenses, and Corcept is exploring a broader distribution network for relacorilant.
Discover what executives don't want to reveal in conference calls
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet